Experimental Leukemia Drug Effective In Most Patients Who Don't Benefit From Other Treatments: Trial
AbbVie is developing the once-daily pill in partnership with Roche Holding AG. In the ongoing study, 72 percent of patients
experimental leukemia drug effective patient benefit treatment trial abbvie develop daily pill partnership roche holding ag ongoing study percent patient